Long-acting injectable HIV PrEP outperforms commercially available daily pill
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
List view / Grid view
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
Gilead's complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.
Researchers found that the combination of lopinavir-ritonavir HIV antivirals led to rapid symptom improvement in COVID-19 patients.
US researchers have stated a newly approved HIV pre-exposure prophylaxis (PrEP) therapy does not have benefits that warrant its price tag and could deter generic competition.
ViiV Healthcare has filed submissions to the FDA and EMA for the first dispersible formulation of dolutegravir (DTG) for children living with HIV.
According to a recent article, drug companies are developing longer-acting, injectable HIV treatments.
Results from a pivotal trial of a new HIV therapy, show that PRO 140 is an effective, long-acting therapeutic for previously treated HIV-1 infected patients...
The FDA has approved Trogarzo for adult patients whose HIV infections cannot be successfully treated...
Broadly neutralising antibody treatment may target viral reservoir in monkeys...
The FDA has approved Biktarvy a once-daily single-tablet regimen for the treatment of HIV-1 infection...
Technical advances in vaccine production should shorten the time to clinical trials, breaking the logjam of promising new candidate vaccines waiting to be tested...
Clinical trial will compare three antiretroviral drug regimens...
Replacing daily pills with a weekly regimen could help patients stick to their dosing schedule...
Data released from the U.S. President's Emergency Plan for AIDS Relief has shown that the HIV epidemic is coming under control...
A team of scientists have recently discovered how a new drug called JQ1 which is currently in early-phase human cancer trials, can reactivate latent HIV...